Home > Cardiology > ACC 2019 > Vascular Medicine > Early discharge and home treatment feasible for low-risk pulmonary embolism patients

Early discharge and home treatment feasible for low-risk pulmonary embolism patients

Conference
ACC 2019
Trial
HoT-PE

Patients with acute low-risk pulmonary embolism (PE), which includes the absence of right ventricular dysfunction and intracardiac thrombi, can be discharged early and further treated at home with rivaroxaban. This strategy has shown to be effective, safe, as well as feasible in the Home Treatment of Pulmonary Embolism (HoT-PE) trial [1].

The HoT-PE trial was a prospective, international, multicentre, single-arm phase 4 trial with 3-month follow-up (plus 1-year follow-up for survival). Primary outcome was recurrent symptomatic venous thromboembolism (VTE), or death due to recurrent PE, within 3 months of enrolment. A total of 525 patients with objectively confirmed PE within 24 hours of presentation were enrolled. These patients received the first dose of rivaroxaban 15 mg twice daily in the hospital and continued for 3 weeks after discharge, followed by rivaroxaban once daily 20 mg, or 15 mg in select patients for at least 3 months. The mean age of patien...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on